AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04268225 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: US guided dynamic needle tip positioning peripheral intravenous cannulation
Description: Catheterizations will be performed by one of three pediatric intensivists with vast experience in both traditional and US guided DNTP techniques for peripheral intravenous access. The operator will be allowed to independently choose which peripheral vein to cannulate. If necessary, patients will be given supplemental dose of sedation and analgesia in addition to the already given continuous infusions for invasive mechanical ventilation. Before puncture, the limb will be taped and maintained in an optimal position. A tourniquet will be placed proximal to the planned cannulation site. The site of puncture will be disinfected with Chlorhexidine gluconate 0.5% w/v, Alcohol 70% v/v. The choice of catheter will be left to the discretion of the operator. Available PIV cannulas include : 14 GA, 2X45 mm; 17 GA, 1.4X45 mm; 18 GA 1.2X45 mm; 20 GA 1X32mm BD Venflon™ and 24 GA, 0.7X19 mm; 26 GA 0.6X19 mm BD Neoflon™ (Becton Dickinson Infusion Therapy AB, Helsingborg, Sweden).
Study NCT04268225 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional peripheral intravenous cannulation
Description: For traditional insertion technique insertion attempt will be blind or tactile.
Study NCT03508219 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BiOSS LIM C
Description: The BiOSS LIM C (Bifurcation Optimization Stent System, Balton, Warsaw, Poland). The BiOSS LIM C is a dedicated bifurcation stent covered with a mixture of a biodegradable polymer and the antiproliferative substance sirolimus. BiOSS LIM C will be used for treatment of the Left-Main bifurcation, according to its instructions for use.~The Alex-Plus cobaltchromium sirolimus eluting stent (Balton, Warsaw, Poland) will be used for treatment of distal left-main side branches according to its instructions for use (i.e. proximal segments of the left anterior descending and left circumflex arteries as well as the ramus intermedius if the latter vessel is part of a trifurcation).~All other lesions (other than left-main bifurcations) will be treated with XIENCE family everolimus-eluting coronary stent systems.
Study NCT04025970 — intervention group
Intervention type: GENETIC
Intervention: Circulating tumor cell and circulating tumor DNA test
Description: Patient stratification based on presence or absence of suspicious findings of cells and DNA
Study NCT02369965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albuvirtide
Description: albuvirtide 320mg administered intravenously once a week
Study NCT02369965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lopinavir-ritonavir
Description: lopinavir-ritonavir 400/100mg administered orally twice daily
Study NCT02369965 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lopinavir-ritonavir
Description: lopinavir-ritonavir 400/100mg administered orally twice daily
Study NCT02369965 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tenofovir
Description: tenofovir 300mg administered orally once daily
Study NCT02369965 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lamivudine
Description: lamivudine 300mg administered orally once daily
Study NCT02084810 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: activated recombinant human factor VII
Description: All subjects will receive one i.v. (intravenous, into the vein) injection of 90μg/kg.~Each subject will be allocated to two treatment periods separated by a wash-out period of a week.
Study NCT02084810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eptacog alfa (activated)
Description: All subjects will receive one i.v. injection of 90μg/kg. Each subject will be allocated to two treatment periods separated by a wash-out period of a week.
Study NCT00328497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panzem (2-methoxyestradiol) NCD, Avastin (Bevacizumab)
Description: Panzem NCD 1,000 mg, four times daily for 28 consecutive days bevacizumab 5 mg/kg intravenous bolus on Day 1 and Day 15
Study NCT03319238 — intervention group
Intervention type: OTHER
Intervention: ketamine
Description: The aim of this study is to evaluate the safety of use, benefits and risks of repeated use of ketamine for each patient with chronic pain in different structures of pain management.
Study NCT02200172 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: Sublingual 3mg non-animal synthetic source melatonin daily at 21.00 hours (±1 hour).
Study NCT02200172 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04557579 — intervention group
Intervention type: PROCEDURE
Intervention: Clear corneal phacoemulsification and IOL implantation
Description: Clear corneal phacoemulsification and IOL implantation were performed by 2 surgeons (Chao-Kai Chang and Hung-Yuan Lin) by using an identical technique to minimize differences in surgically induced aberrations between groups. The surgical process involved topical anesthesia, a 3-step clear corneal incision (2.75 mm) at 180° (temporal in both eyes), a 5.0-mm continuous curvilinear capsulorhexis, phacoemulsification using the stop-and-chop technique, IOL implantation with an injector, IOL centration, and a sutureless incision. The study IOL models include EDOF Symfony IOL (AMO, Santa Ana, CA, USA), bifocal Restor +2.5D IOL (Alcon, Fort Worth, TX, USA), and monofocal Sensar AR40e IOL (AMO, Santa Ana, CA, USA).
Study NCT02449031 — intervention group
Intervention type: DRUG
Intervention: TOBI® PODHALER®
Study NCT02449031 — intervention group
Intervention type: DRUG
Intervention: TOBI®
Description: tobramycin inhalation solution, USP
Study NCT02449031 — intervention group
Intervention type: DRUG
Intervention: Bethkis®
Description: tobramycin inhalation solution
Study NCT02449031 — intervention group
Intervention type: DRUG
Intervention: Cayston®
Description: aztreonam for inhalation solution
Study NCT02422446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icosapent ethyl
Description: icosapent ethyl is eicosapentaenoic acid, an omega-3 fatty acid that naturally occurs in fish
Study NCT02863185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitavastatin
Study NCT02863185 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Study NCT01603693 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bio-Oss (by Geistlich)
Description: Guided Bone Regeneration (GBR) will be done with no changes from the common (Dahlin 1988). Patients will be given local anasthesia, full thickness mucoperiosteal flap will be raised to expose the bone area that needs augmentation, bone substitute will be placed over the bony crater and covered with a collagen membrane (Bio-Gide, geistlich, FDA and CE approved). Mucoperiosteal flap will be sutured and patients will be instructed to a check-up routine as accepted after this kind of procedure.
Study NCT01603693 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BondBone (by Augma)
Description: Guided Bone Regeneration (GBR) will be done with no changes from the common (Dahlin 1988). Patients will be given local anasthesia, full thickness mucoperiosteal flap will be raised to expose the bone area that needs augmentation, bone substitute will be placed over the bony crater and covered with a collagen membrane (Bio-Gide, geistlich, FDA and CE approved). Mucoperiosteal flap will be sutured and patients will be instructed to a check-up routine as accepted after this kind of procedure.
Study NCT03588910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: 50 tablets of acetaminophen 500mg (1-2 tablets every 6 hours as needed)
Study NCT03588910 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: 50 tablets of acetaminophen 500mg (1-2 tablets every 6 hours as needed)
Study NCT03588910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 600 mg
Description: 25 tablets ibuprofen 600mg (1tablet every 6 hours as needed)
Study NCT03588910 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 600 mg
Description: 25 tablets ibuprofen 600mg (1tablet every 6 hours as needed)
Study NCT03588910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: The number of tablets of oxycodone prescribed is the only difference between the two arms.
Study NCT03588910 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: The number of tablets of oxycodone prescribed is the only difference between the two arms.
Study NCT04270526 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bicarbonate protocol
Description: Intradetrussor treatment with 50 mL 1% lidocaine + 45ml of 0.9% normal saline + 5 mL 8.4% sodium bicarbonate
Study NCT04270526 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard protocol
Description: Intradetrussor treatment with 50 mL 1% lidocaine + 50ml of 0.9% normal saline
Study NCT01704495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5069
Description: AZD5069 oral capsules self-administered twice daily.
Study NCT01704495 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral capsules self-administered twice daily.
Study NCT01419756 — intervention group
Intervention type: DEVICE
Intervention: VentriPoint Medical System
Description: The Knowledge Based Reconstruction (KBR) method generates a 3D reconstruction of the RV based on the Piecwise smooth subdivision surface method but without requiring manual border tracing. Instead KBR reconstructs a new patient's ventricular surface from the placement of anatomic landmark points on a 2D ultrasound image
Study NCT01544985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 88% sucrose po solution
Description: 88% sucrose solution (Syrup B.P.)
Study NCT01544985 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo po
Description: sterile water
Study NCT01969149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Study NCT01969149 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Study NCT00319449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: 10 mg ezetimibe, orally, daily for 6 weeks, added to ongoing treatment with 10 mg atorvastatin
Study NCT00319449 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 mg/day matching placebo to ezetimibe, orally, daily for 6 weeks, added to ongoing 10 mg atorvastatin
Study NCT00319449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg
Description: 10 mg/day atorvastatin, orally, (ongoing treatment in participants)
Study NCT00319449 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin 10 mg
Description: 10 mg/day atorvastatin, orally, (ongoing treatment in participants)
Study NCT01025193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belimumab
Description: Belimumab is a fully human monoclonal antibody that recognizes and inhibits BLyS ®. BLyS ® is a B-lymphocyte stimulator protein which plays a role in the development of B lymphocyte cells into plasma B cells, which then produce antibodies that can sensitize a potential transplant recipient. At the time of this trial, belimumab was not yet FDA approved and was being studied in clinical trials for the treatment of systemic lupus erythematosus. Until this trial, it had not yet been used in the transplant setting.
Study NCT01198223 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: garlic , nystatin
Description: mouthwash
Study NCT04024969 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: T2* MRI
Description: Research T2\* weighted MRI sequence
Study NCT04024969 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Lumbar puncture to test for presence of unmatched oligoclonal bands
Description: Current clinical standard practice
Study NCT02645240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin injection
Description: Intravenous heparin injection in patients with acute mesenteric ischemia and evaluating their response within 24 hours
Study NCT01011816 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BIOSTAT BIOLOGX
Description: One injection of up to 4 mL of BIOSTAT BIOLOGX Fibrin Sealant into a single lumbar intervertebral disc using the Biostat Delivery Device
Study NCT01011816 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: One injection of up to 4 mL of saline using the Biostat Delivery Device
Study NCT02250898 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial Massage Therapy
Description: Myofascial Massage Therapy is a manual massage therapy consisting of the following techniques: fascial stretch, circular friction, deep fascial restriction release, arm pull, side latissimus dorsi stretch, twisting, moist heat application, cold therapy, and lymphatic drainage.
Study NCT02250898 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Global Relaxation Massage
Description: Global Relaxation Massage is a manual massage therapy consisting of a full body relaxation massage that includes light kneading and stroking in order to restore a sense of well- being
Study NCT02770716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terlipressin
Description: Terlipressin solution for injection
Study NCT02770716 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo solution for injection
Study NCT03119064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nanoliposomal Irinotecan
Description: Three patients will be accrued to level 1. If no dose limiting toxicities are observed following completion of 4 weeks (2 cycles) of treatment then accrual to dose level 2 will proceed (patients must be evaluated prior to their cycle 3 treatment and this will be used to confirm DLTs). If a DLT is observed in one of the first 3 patients in a dose level, then accrual for that level will be expanded to 6 patients. Accrual will continue in this way until the MTD of nanoliposomal irinotecan with temozolomide 50mg/m2/day is determined. Two or more instances of DLT in a cohort of 6 patients will result in the preceding dose level being defined as the MTD. If two or more instances of DLT in a cohort of 6 patients occurs in dose level 1 then dose level -1 of nanoliposomal irinotecan will be investigated. After determination of the MTD, the final cohort will be expanded so that a total of 25 patients are treated on study. The final cohort will be treated at the MTD.
Study NCT03119064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Three patients will be accrued to level 1. If no dose limiting toxicities are observed following completion of 4 weeks (2 cycles) of treatment then accrual to dose level 2 will proceed (patients must be evaluated prior to their cycle 3 treatment and this will be used to confirm DLTs). If a DLT is observed in one of the first 3 patients in a dose level, then accrual for that level will be expanded to 6 patients. Accrual will continue in this way until the MTD of nanoliposomal irinotecan with temozolomide 50mg/m2/day is determined. Two or more instances of DLT in a cohort of 6 patients will result in the preceding dose level being defined as the MTD. If two or more instances of DLT in a cohort of 6 patients occurs in dose level 1 then dose level -1 of nanoliposomal irinotecan will be investigated. After determination of the MTD, the final cohort will be expanded so that a total of 25 patients are treated on study. The final cohort will be treated at the MTD.
Study NCT03392090 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: More Good Days video&brief questionnaire
Description: Help patients with advanced cancer think about what a good day means to them and to help them think about questions they may have for their physicians when discussing treatments
Study NCT02415361 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cleft lip and palate
Description: Comparison between Arm A who will receive standard care and Arm B who will receive systematic follow up performed by a special trained nurse will be performed.
Study NCT03423706 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: the new model of haplo-HSCT for r/r B-ALL
Description: take advantage of high-dose CTX、CD19-CART、donor CD34+HSC and Tregs to create a new model of haplo-HSCT for the patients in r/r B-ALL,to improve the quality of HSCT.
Study NCT00003966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: defibrotide
Study NCT01170026 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Check-up/ Individual MI
Description: The 2-session intervention protocol consists of an individual motivational interview plus the Family Check-Up (Dishion \& Kavanagh, 2003), a family based motivational interview. The experimental protocol provides a thorough assessment of both individual and family strengths and weaknesses with respect to substance use prevention and school attendance/performance.
Study NCT01170026 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual and family psychoeducation
Description: Families in PE will return for the same number of visits as the IMI and FCU sessions of the IMI/FCU condition. An interventionist will review a set of educational materials with the parents regarding teen SU use, truancy and risk behaviors and parenting a teenager. A similar set of materials will be reviewed with the adolescent
Study NCT02059512 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group 1
Description: Coronary artery bypass grafting with intramyocardial administration of autologous bone marrow mononuclear cells 0.2 ml - 10 injection in the zone of blood supply LAD.
Study NCT02059512 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Group 0
Description: Coronary artery bypass grafting with intramyocardial administration of 0.9 % NaCl (sodium chloride) 0.2 ml - 10 injection in the zone of blood supply LAD.
Study NCT02059512 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group 2
Description: Coronary artery bypass grafting with intramyocardial and intracoronary administration of autologous bone marrow mononuclear cells intramyocardial administration 0.2 ml - 10 injection in the zone of blood supply LAD.
Study NCT02360969 — intervention group
Intervention type: OTHER
Intervention: Examination of the eye
Description: Before planed surgery, an ophthalmologist measures the patient's visual acuity and realise an oculomotor examination. Measurement the refraction and the axial length of the eye is performed. Photographs wakefulness are performed.~During surgery, participation in this study does not involve any change in the course of anesthesia and surgery.~Pictures of the eye will be performed under general anesthesia.~Timing photos will be dictated by the values of BIS and train-of-four (TOF). Photos will be conducted at different times, with the top given by the anesthetist under the following conditions:~Deep anesthesia: BIS \<50 Deep anesthesia and muscle relaxation: BIS \<50 and TOF 0/4
Study NCT03834922 — intervention group
Intervention type: OTHER
Intervention: Prospective data collection
Description: No intervention. It's a prospective data collection.
Study NCT04103125 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Janesse® is a sterile, injectable, non-pyrogenic, re-absorbable medical product made of reticulated hyaluronic acid of non-animal origin, produced via bacterial fermentation.
Description: The subjects will receive at baseline the first IMD by the Investigator in accordance with the CIP
Study NCT03598790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Description: Subjects will receive bimekizumab at pre-specified time-points.
Study NCT02229266 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK cells
Study NCT02229266 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: 1 cycle of consolidation chemotherapy with high-dose cytarabine
Study NCT04844164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol 15000 UNT/ML Oral Solution
Description: A single dose (150,000 IU) of cholecalciferol aqueous solution per os
Study NCT01931683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: remifentanil
Description: The concentration of remifentanil was determined by modified Dixon's up-and-down method, starting from 1.0 ng/ml (0.2 ng/ml as a step size)
Study NCT01931683 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laryngeal mask airway (LMA)
Description: LMA was removed when the patients opened their eyes, and spontaneous respiration and adequate tidal volume and ventilatory frequency were confirmed
Study NCT00516178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fish oil emulsion
Description: 0.2 g/kg FO, 3 times in 24 hours, infused over 3 hours each in cardiac surgery, or continuous infusion of 0.6 g/kg post PTCA
Study NCT00516178 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 3 infusions, perioperative or post-PTCA
Study NCT02247141 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Subgam® (Human Normal Immunoglobulin Solution)
Study NCT02980198 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IFN-Kinoid
Description: IM administration
Study NCT02980198 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IM administration
Study NCT02980198 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ISA 51
Description: adjuvant
Study NCT02980198 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: ISA 51
Description: adjuvant
Study NCT00662415 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mirror-box treatment
Description: 15 minutes daily for 4 weeks
Study NCT00662415 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: observation
Description: observation